Why the study?
Do AT1 receptor antagonists prevent dopamine degeneration and microglial activation in the MPTP model of Parkinson's disease?
Population
Primary mesencephalic cultures and mice (MPTP model of Parkinson's disease)
Design
Preclinical
Key result
AT1 receptor antagonists inhibited dopamine degeneration and early microglial and NADPH activation in MPTP-treated mice and primary mesencephalic cultures.
Authors
Loading...
AT1 antagonists merit exploration as neuroprotective agents in Parkinson's; leaves open translation from MPTP models to clinical use.
Do AT1 receptor antagonists prevent dopamine degeneration and microglial activation in the MPTP model of Parkinson's disease?
The brain angiotensin system may mediate the inflammatory response in Parkinson's disease, suggesting AT1 receptor antagonists as a potential neuroprotective target.
Joglar et al. (2009) studied Parkinson's disease (MPTP model). AT1 receptor antagonists was evaluated on Dopamine degeneration and microglial/NADPH activation. AT1 receptor antagonists inhibited dopamine degeneration and early microglial and NADPH activation in MPTP-treated mice and primary mesencephalic cultures.